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Abstract
Background: Catheter ablation (CA) of atrial fibrillation (AF) requires an intensified peri-inter-
ventional anticoagulation scheme to avoid thromboembolic complications. In patients with cardiac or 
extracardiac artery disease, an additional antiplatelet treatment (AAT) is at least temporally necessary 
especially after a percutaneous intervention with stent implantation. This raises the question whether 
these patients have a higher peri-interventional bleeding risk during CA of AF.
Methods: The data of 1235 patients with CA of AF were retrospectively analyzed in terms of bleeding 
events, ablation type, antithrombotic medication and comorbidities such as coronary artery disease and 
components of the HAS- BLED score. Peri-interventional bleeding events were classified in accordance 
with the BARC classification. Differentiations were made between slight femoral bleeding (based on type 1),  
severe femoral bleeding and pericardial effusion without pericardiocentesis (based on type 2) with the 
need of further hospitalization, the need of transfusion (based on type 3a) and pericardial tamponades 
requiring pericardiocentesis (based on type 3b). 
Results: 1131/1235 (91.6%) patients were exclusively under anticoagulation and 187 (15.3%) patients 
were also on AAT. There were no statistically significant differences in type 1 and 3b bleeding complica-
tions or the occurrence of femoral pseudoaneurysms between both groups. However, type 2/3a bleeding 
complications, mostly femoral bleedings, were significantly more frequent in the patient group with AAT 
(3.2% vs. 7.5%, p = 0.006). 
Conclusions: An additional antiplatelet therapy increases the risk of severe femoral bleeding events 
during CA of AF. It appears reasonable to perform the elective procedure of AF ablation after the dis-
continuation of AAT. (Cardiol J 2018; 25, 2: 213–220)
Key words: atrial fibrillation ablation, antiplatelet medication, anticoagulation, femoral 
bleedings, percardial tamponades, pseudoaneurysms
Introduction
Atrial fibrillation (AF) is the most common 
sustained heart rhythm disorder in humans, es-
pecially at an increased age. In addition to rate 
control, rhythm control is an optional strategy for 
patients with symptomatic AF [1]. The efficacy of 
currently available antiarrhythmic drugs for rhythm 
control of AF patients is poor and AF relapses 
are common [2]. In patients with drug-refractory 
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paroxysmal AF, the results of multiple clinical 
trials have demonstrated that catheter ablation 
(CA) is superior to antiarrhythmic drugs therapy 
in long-term maintenance of sinus rhythm [3]. 
The intervention is highly elective and subject to 
stringent safety requirements. Even minor com-
plications are undesirable. Patients undergoing 
CA of AF have a transient increased risk of throm-
boembolism during, immediately after and for 
several weeks to months after the procedure [4]. 
This is because transseptal sheath placement, in-
sertion of electrode catheters and radiofrequency 
energy application can precipitate thrombus for-
mation. Substantial areas of damaged left atrial 
endothelium become a nidus for thrombus for-
mation. This thrombus is at high risk of causing 
peri- and post-interventional strokes. Therefore, 
a peri- and post-interventional anticoagulation is 
mandatory. Depending on the CHA2DS2VASc score 
(C = congestive heart failure, H = hypertension, 
A = age > 75 years, D = diabetes, S = stroke, 
V = vascular disease, A = age > 65 years, S = sex 
category woman) and the HAS-BLED score 
(H = hypertension, A = abnormal kidney or liver 
function, S = stroke, B = history of bleeding, 
L = labile international normalized ratio [INR], 
E = elderly > 65 years, D = drugs), life-long 
anticoagulation may be necessary [1]. But it may 
cause an increased risk of bleeding [5]. Comorbidi-
ties such as coronary artery disease and peripheral 
artery disease require an additional antiplatelet 
treatment (AAT), especially after a percutaneous 
intervention and stent implantation. Therefore, it 
raises the question whether patients with a com-
bined antithrombotic therapy and anticoagulation 
have a higher peri-interventional risk of bleeding. 
Under examination herein were the various bleed-
ing complications in CA of AF and clarified if they 
occurred more often under combined anticoagula-
tion and AAT compared to anticoagulation alone.
Methods 
Retrospectively, the data of 1235 patients 
with CA of AF, during the period of 2005–2015, at 
the Heart Center of University Hospital Tuebin-
gen, were analyzed using electronical datasets 
of patient charts. The study got approval by the 
local ethics committee. All adult patients (> 18 
years) who underwent CA of AF during this period 
were included in the analysis. Patient data were 
analyzed in terms of patient characteristics and 
in terms of bleeding complications. The follow-
ing data were retrospectively assessed: age, sex, 
type of antiplatelet medication (acetylsalicylic acid 
[ASA], clopidogrel, ticagrelor, prasugrel) and anti-
coagulation before ablation (type of non-vitamin K 
oral anticoagulant [NOAC], vitamin K antagonists 
[VKA], heparin, none), the usage of one or two 
antiplatelet medications, ablation type and the pres-
ence of coronary artery disease. Additionally, the 
components of HAS-BLED score were collected 
for risk stratification: history of hypertension, age 
> 65 years, history of stroke, medication predispos-
ing to bleeding (antiplatelet agents, non-steroidal 
anti-inflammatory drugs), history of prior bleed-
ing events, labile INR (time in therapeutic range 
< 60%), hepatic impairment (cirrhosis or serum 
bilirubin > 2 × normal or aspartate aminotrans-
ferase [AST]/alanine aminotransferase [ALT]/
alkaline phosphatase [AP] > 3 × normal, renal 
insufficiency (on dialysis, after kidney transplanta-
tion or with creatinine concentration > 2.26 mg/dL 
or > 200 µmol/L) and alcohol or drug abuse [6]. 
Patients were separated into two groups: one 
group of patients with only anticoagulation and 
a second group with AAT plus anticoagulation. 
The bleeding events as endpoints were classified 
according to Bleeding Academic Research Con-
sortium (BARC) [7]. Modified, the bleeding types 
1-3b were used here and are defined as follows: 
slight bleedings (type 1) defined as slight femoral 
bleeding at the puncture site. Type 2 bleedings 
constituted severe femoral bleeding events, which 
required re-installation of a pressure bandage and 
re-sonographic control. In casesof abnormal find-
ings in the examination of the inguinal region for 
example one-sided flow noise, pulsating swelling 
or large hematoma, the patient underwent vascular 
ultrasound. In this way, pseudoaneurysms could 
be determined. Type 2 also included patients with 
a pericardial effusion without the need for a peri-
cardiocentesis. Type 3a bleedings required a trans-
fusion. A pericardial tamponade with the need for 
pericardiocentesis was assigned to type 3b. These 
events prolonged hospitalization. Normally, the 
patients were hospitalized for 2 days after CA but 
if there was a bleeding complication the hospitaliza-
tion was prolonged until the patients were stable 
in terms of hemoglobin or the aneurysm was no 
longer perfused, or no pericardial effusion could be 
detected after repeated echocardiographic control.
Ablation procedure
Preprocedural transoesophageal echocardi-
ography was performed to exclude intracardiac 
thrombi in all patients. Vascular ultrasound was 
only used in difficult femoral conditions. The abla-
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tion procedure was performed under sedation with 
a continuous infusion of propofol. For CA of AF, 
circumferential pulmonary vein isolation (PVI) and 
the cryoballoon PVI were used. During the ablation 
a 6-F decapolar catheter (Bard, Electrophysiology 
Division, Lowell, MA, USA) was positioned within 
the coronary sinus via the left femoral vein. 
A puncture of the radial artery with a 4-F sheath was 
performed for invasive control of blood pressure. 
In the cryoablation group a 14 F sheath was placed 
in the left atrium via the right femoral vein after 
a single transseptal puncture. In the radiofrequency 
(RF) ablation group a single transseptal puncture 
was performed and two sheaths, 8 F nonsteerable 
and 11 F steerable, were placed into the left atrium 
through one puncture site via the right femoral 
vein. A temperature probe in the esophagus (Sen-
sitherm, St. Jude Medical) at the level of the left 
atrium was used with a cut off value of 39.0°C. 
A geometry of the left atrium was created using 
the NAVX- or the CARTO-system and a circumfer-
ential pulmonary vein ablation controlled by simul-
taneous mapping with a circular catheter placed in 
the pulmonary vein and with ipsilateral pulmonary 
vein ablation using irrigated RF energy application. 
In addition, a circular mapping catheter was placed 
in the left superior or left inferior pulmonary vein. 
After completing the circumferential ablation lines 
PVI was reevaluated using the circular mapping 
catheter. After the procedure patients got a com-
pression bandage for 12 h.
Anticoagulation strategies
The antiplatelet medication was not interrupt-
ed during ablation. VKA were continued. In cases 
of INR < 1.8 low-molecular-weight heparin, or in 
cases of glomelural filtration rate (GFR) < 30 mL/ 
/min intravenous heparin was given before and after 
ablation. However, NOACs were interrupted 24–48 h 
prior to ablation. During ablation, intravenous 
heparin was continuously administered to keep 
activated clotting time in the range of 300–400 s. 
After ablation heparin was not antagonized with 
protamine, but was continuously used until INR ex-
ceeded 2.0, or NOACs were continued. In patients 
with NOAC treatment before ablation and GFR 
> 50 mL/min an accelerated loading dose scheme 
of dabigatran was used [8], otherwise the preceding 
NOAC was continued. Therapeutic anticoagulation 
was continued for at least 3 months.
Statistical analysis
The results of patient characteristics were 
expressed as mean ± standard deviation. The dif-
ferences in percentage were analyzed using the 
c2 test. The associations of risk variables with the 
significant endpoints were tested by univariate and 
multivariate logistic analyses. Only the variables, 
that were univariate significant, were included in 
multivariate analysis. The significance level was 
set at p < 0.05.
Results
Table 1 shows the patient characteristics. 
Among the 1235 patients were 432 (35%) women. 
The average age was 61.0 ± 10.4 years. 937 (75.9%) 
Table 1. Patients’ characteristics.
Number of patients 1235
Age [years] 61.0 ± 10.4
Females 432 (35.0%)
Coronary artery disease 223 (18.1%)
Method of ablation:
Radiofrequency energy 937 (75.9%)
Cryoenergy 298 (24.1%)
Platelet inhibitor before ablation:
Acetylsalicylic acid 176 (14.3%)
Clopidogrel 21 (1.7%)
Prasugrel 1 (0.1%)
Ticagrelor 4 (0.3%)
One platelet inhibitor 172 (13.9%)
Two platelet inhibitors 15 (1.2%)
Anticoagulation before ablation:
Vitamin K antagonists 599 (48.5%)
Rivaroxaban 198 (16%)
Dabigatran 119 (9.6%)
Apixaban 30 (2.4%)
Heparin 185 (15,1%)
None 229 (18.4%)
HAS-BLED score 1.28 ± 0.9
Age > 65 years 458 (37.1%)
Hypertension 795 (64.4%)
Renal insufficiency 5 (0.4%)
Hepatic impairment 28 (2.3%)
Stroke history 76 (6.2%)
Prior major bleeding or  
predisposition to bleeding
18 (1.5%)
Labile international normalized  
ratio setting
3 (0.2%)
Medication predisposing to  
bleeding (platelet inhibitor)
187 (15.1%)
History of alcohol or drug usage 10 (0.8%)
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patients were treated with circumferential PVI 
with RF energy and 298 (24.1%) with cryoballoon 
PVI. 223 (18.1%) patients had coronary artery 
disease. 204 patients had any type of antiplatelet 
medication. ASA was used in 176 (14.3%) patients, 
clopidogrel in 21 (1.7%), prasugrel in 1 (0.1%) and 
ticagrelor in 4 (0.3%). 1131/1235 (91.6%) patients 
had anticoagulation before the procedure. 599 
(48.5%) patients were on VKA, 198 (16%) on ri-
varoxaban, 119 (9.6%) on dabigatran, 30 (2.4%) on 
apixaban and 185 (15.1%) only on low molecular 
weight heparin. However, there was only 1 patient 
with IV heparins prior to ablation, which was 
therefore assigned to the low molecular weight 
heparin group. 229 (18.5%) of the patients had no 
anticoagulation prior to CA. 124 (10%) patients 
were only on antiplatelet medication. In addition 
to anticoagulation, 15 (1.2%) patients had an addi-
tional dual antiplatelet therapy, which means they 
had a triple therapy (TT). Patients with TT had 
a percutaneous intervention within the prior 1–6 
months (depending on the type of stent). In 172 
(13.9%) of the patients only 1 antiplatelet drug was 
taken additionally, so they had a dual therapy (DT), 
or the antiplatelet was singularly used. Patients 
under DT mainly took this due to a 1 to 12-month 
previous percutaneous intervention (depending on 
the type of stent), a small number due to a high 
cardiovascular risk profile potentially compromis-
ing the progress of coronary or peripheral artery 
disease. 
The investigation of the components of the 
HAS-BLED score revealed the following results: 
458 (37.1%) patients were > 65 years old, 795 
(64.4%) had hypertension, 76 (6.2%) had a history 
of stroke, 3 (0.2%) had a labile INR, 5 (0.4%) suf-
fered from renal insufficiency and 28 (2.3%) from 
hepatic impairment, 18 (1.5%) had a prior major 
bleeding or a predisposition to bleeding and 10 
(0.8%) had a history of alcohol or drug usage.
Further research with regard to bleeding 
complications depending on AAT presented the 
following (Table 2). According to BARC 1 (slight 
femoral bleedings) there was no statistically sig-
nificant difference between the groups of sole 
anticoagulation and AAT (43 (4.1%) vs. 12 (6.4%), 
p = 0.157). The same could be detected for peri-
cardial effusions without the need for pericar-
dial puncture (BARC 2) (49 [4.7%] vs. 6 [3.2%], 
p = 0.372). Regarding pericardial tamponades 
requiring puncture (BARC 3b) a significant re-
sult  could not be achieved (13 [1.2%] vs. 0 [0%], 
p = 0.126). No statistical difference was shown 
in the formation of femoral pseudoaneurysms 
between both groups (38 [3.6%] vs. 6 [3.2%], 
p = 0.778). Only in severe femoral bleedings that 
were assigned to both BARC 2 and 3a, a significant 
difference could be detected (p = 0.006). 34 (3.2%) 
patients were revealed with anticoagulation mono-
therapy and 14 (7.5%) in patients with AAT. 
In the group with severe femoral bleeding, 
HAS-BLED score was significantly higher than in 
the group with light femoral bleeding (1.8 ± 1.0 
vs. 1.2 ± 0.9, p < 0.001). 
Table 3 shows a subgroup analysis of the risk 
of bleeding based on the various parameters of the 
HAS-BLED score separately for patients receiv-
ing only a single oral anticoagulant versus those 
receiving additional antiplatelet therapy. Patients 
without AAT had more frequently had a stroke in 
the past. On the other hand, patients under AAT 
had a significantly higher HAS-BLED score. There 
are no differences in terms of other components 
such as age, hypertension, renal insufficiency, he-
patic impairment, history of prior major bleeding, 
labile INR setting or history of alcohol and/or drug 
use (p > 0.05 for all).
In a binary regression analysis (Table 4), 
older age (p = 0.001) and the presence of an AAT 
(p = 0.031) were independent predictors for the 
endpoint “severe femoral bleeding”. In contrast, 
the use of interrupted NOACs (p = 0.007) inde-
pendently decreased the risk. Other components 
of the HAS-BLED score such as renal and hepatic 
impairment, hypertension, prior major bleeding, 
history of stroke, history of alcohol or drug usage, 
Table 2. Effect of additional platelet inhibitors on bleeding complications.
Platelet inhibitor No platelet inhibitor P
Slight femoral bleeding (BARC 1) 12 (6.4%) 43 (4.1%) 0.157
Severe femoral bleeding (BARC 2/3a) 14 (7.5%) 34 (3.2%) 0.006
Pseudoaneurysms 6 (3.2%) 38 (3.6%) 0.778
Pericardial effusion (puncture not required) (BARC 2) 6 (3.2%) 49 (4.7%) 0.372
Pericardial effusion (puncture required) (BARC 3b) 0 (0.0%) 13 (1.2%) 0.126
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labile INR and ablation type did not independently 
predict the endpoint (p > 0.05 for all). 
The statistical relationship between severe 
bleeding events and risk variables was determined 
by the odds ratio as shown in Figure 1. 
Patients under VKA therapy had the highest 
risk of severe femoral bleeding (5.7%), followed 
by patients without anticoagulation (4.8%). These 
patients, however, had a higher HAS-BLED score 
(1.4 ± 1.0 vs. 1.2 ± 0.9, p = 0.012) compared to 
the other patients. Because of this, no anticoagula-
tion was often performed before the procedure in 
this group. Patients with NOAC therapy had the 
lowest risk of severe femoral bleeding (0.9%). Pa-
tients under heparin therapy had a severe femoral 
bleeding risk of 1.6%.
Discussion
Atrial fibrillation is the most common sustained 
heart rhythm disorder. In drug refractory therapy, 
an ablation can be performed. The procedure is 
usually highly elective. In addition to thrombem-
bolism, bleeding events are the most common 
complications. These should be kept as low as pos-
sible. In this context, it is important to determine 
Table 3. Effect of additional platelet inhibitors on bleeding complications depending on HAS-BLED 
score components.
Platelet inhibitor  
(n = 187)
No platelet inhibitor 
(n = 1048)
P
HAS-BLED score 2.1 ± 0.8 1.1 ± 0.8 < 0.001
Age > 65 years 66 (35.3%) 392 (37.4%) 0.321
Hypertension 121 (64.7%) 674 (64.3%) 0.494
Renal insufficiency 1 (0.5%) 4 (0.4%) 0.561
Hepatic impairment 4 (2.1%) 24 (2.3%) 0.578
Stroke history 2 (1.1%) 74 (7.1%) 0.001
Prior major bleeding or predisposition to bleeding 5 (2.7%) 13 (1.2%) 0.123
Labile international normalized ratio setting 0 (0.0%) 3 (0.3%) 0.611
History of alcohol or drug usage 0 (0.0%) 10 (1.0%) 0.375
Table 4. Univariate and multivariate binary logistic regression analysis for prediction of severe femoral 
bleeding events (BARC type 2/3a).
Variable Univariate analysis Multivariate analysis
OR (95% CI) z p OR (95% CI) z p
Age > 65 years 2.46 (1.37–4.42) 9.10 0.003 2.60 (1.44–4.70) 10.1 0.001
Hypertension 1.69 (0.87–3.29) 2.40 0.121
Renal insufficiency 6.29 (0.69–57.49) 2.66 0.103
Hepatic impairment 3.01 (0.90–10.64) 3.22 0.072
History of stroke 0.65 (0.15–2.75) 0.33 0.562
Prior major bleeding or predisposition  
to bleeding
3.18 (0.71–14.25) 2.29 0.130
Labile international normalized ratio*
Medication usage predisposing  
to bleeding (platelet inhibitor)
2.41 (1.27–4.59) 7.21 0.007 2.05 (1.07– 3.95) 4.64 0.031
History of alcohol or drug usage*
NOAC 0.22 (0.08– 0.63) 8.15 0.004 0.24 (0.85–0.68) 7.22 0.007
Ablation type 0.72 (0.34–1.5) 0.78 0.38
*No events for these properties; CI — confidence interval; NOAC — non-vitamin K oral anticoagulant; OR — odds ratio
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the predictors of bleeding complications. Some 
patients suffer from AF as well as from cardiac or 
extracardiac atherosclerosis, which makes it often 
necessary to take an additional platelet inhibition, 
especially after stent implantation. It is important 
to investigate whether these patients are more 
likely to have bleeding complications and derive 
strategies for prevention. Previous studies were 
limited to the effects of solely anticoagulants on 
peri-interventional bleeding risks, vascular dam-
age and pericardial tamponades associated with 
CA of AF [5, 9–16]. Data on the risk of AAT in 
patients undergoing CA of AF does not seem to 
be well studied.
In this study patients with AAT had a signifi-
cantly higher risk of severe femoral bleeding. This 
risk was more than double in the retrospective 
study. However, there were no significant differ-
ences in terms of slight femoral bleedings, pericar-
dial effusions and femoral pseudoaneurysms. The 
formation of pseudoaneurysms might be dependent 
on the interventionists, the type of puncture, the 
patient’s anatomy and the compression bandage. 
Nevertheless, the slight bleeding complications 
are probably underestimated because of the nature 
of a retrospective study design, which were also 
reported in other studies [17]. 
The use of DT or TT in patients with AF undergo-
ing percutaneous coronary intervention (PCI) have a 
much broader database. Patients with TT and subse-
quent re-PCI have a higher risk of major bleedings 
than patients with DT or dual antiplatelet therapy 
alone [18, 19]. On the other hand, patients under TT 
have a significantly lower risk of thromboembolism 
[18, 20], so it is associated with lower all-cause mor-
tality [18] due to a reduced risk of stent thrombosis 
[21] by an adequate antiplatelet therapy. 
On the other hand, the HAS-BLED score was 
significantly increased in patients with severe 
femoral bleedings and in patients with platelet 
inhibitor. The latter is to be expected since the fact 
of a platelet inhibitor is thus included in this score. 
Basically, the oral anticoagulation (OAC) should be 
given carefully in patients with a HAS-BLED score 
≥ 3. But, the HAS-BLED score alone should not 
exclude patients from a possible OAC [21].
At the same time, patients with a higher HAS-
BLED score usually have a high risk of stroke as 
well (CHA2DS2VASc), so they benefit from an OAC 
disproportionately. The present data shows that 
patients without platelet inhibitor had significantly 
more strokes in  prehistory. This is because most 
of the patients were already under OAC due to an 
AF associated stroke in the past. 
229 patients had no anticoagulation prior to 
the procedure. 124 of these had only antiplate-
let medication. These were young patients with 
CHA2DS2VASc score 0 or 1 or high HAS-BLED 
score and thus high bleeding risk. 
The singular use of ASA or no use of anti-
thrombocytic therapy in patients with CHA2DS2-
VASc score 0 or 1 and lack of risk factors was 
consistent with the former European Society of 
Cardiology (ESC) guidelines [22]. It is now recom-
mended to perform oral anticoagulation in patients 
with CHA2DS2VASc score 1. In case of CHA2DS2- 
VASc score 0 or in women under 65 years no 
permanent anticoagulation is recommended [23].
In the context of a regression analysis, age 
and antiplatelet medication as components of the 
HAS-BLED score were responsible for the severe 
femoral bleeding events as independent risk fac-
tors. The fact that increased age has a meaningful 
influence on bleeding complications is well known 
Figure 1. Forest plot of univariate logistic regression analysis for different risk variables; CI — confidence interval; 
NOAC — non-vitamin K oral anticoagulant.
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[24]. Despite the small number of patients with 
AAT, it can be identified as an independent predic-
tor for bleeding events in CA of AF. The variables 
of unstable INR, alcohol and drug abuse seem to 
be associated with a small risk, but cannot be ex-
ploited due to the low drop rate. Limited liver and 
renal function are associated with increased risk 
of bleeding. Here too, the case numbers are very 
small. In addition, the liver and renal insufficiencies 
are very strict and highly defined in the HAS-BLED 
score, namely cirrhosis or serum bilirubin > 2 × 
normal or AST/ALT/AP > 3 × normal for hepatic 
impairment and dialysis, transplant, creatinine 
> 2.26 mg/dL or > 200 µmol/L for renal insuf-
ficiency [6]. Patients, who meet these criteria, 
are rarely subjected to a CA of AF. Due to the 
retrospective design, the cases for previous severe 
bleeding could be underestimated.
Here, the use of NOAC is associated with 
a lower risk of bleedings. But here NOACs were 
interrupted 24–48 h before ablation, so a lower 
dose level has to be assumed and this result is 
inaccurate. It could also be shown that there is 
a significantly lower risk of bleeding under NOAC 
than under VKA. Other studies proved the same 
[12, 17]. The use of NOAC became more attractive 
the later years due to both more experience and 
resulting better controllability and demonstrated 
lower bleeding risk in general [9–17]. 
However, this study is mainly concerned with 
the question of bleeding probability under AAT. 
To minimize the risk of bleeding events, the 
selection of patients is important. There are dif-
ferent criteria that should be considered before CA 
of AF such as duration and symptoms of AF, age, 
predisposing medication and comorbidities. Also, 
obesity might be a risk factor due to a difficult 
punctuation situation. Further, in order to reduce 
the bleeding complications, the pre-, peri- and 
post-interventional femoral monitoring could be 
extended as well as the duration of the compression 
bandage, but the latest was only under considera-
tion of the respective risk of the development of 
thrombosis.
Limitations of the study
A limitation of this study there need to be 
mention of the retrospective and oberservational 
nature of the study design. Furthermore, this ob-
servation study was carried out over a long period 
of time. During this time, various anticoagulation 
and antiplatelet regimes were used. Especially with 
the introduction of NOACs and their lower risk of 
bleeding need to be mentioned here. 
Conclusions
When determining ablation, both the risk of 
bleeding by calculating the HAS-BLED score and 
the risk of thromboembolism by calculating the 
CHA2DS2VASc score should be assessed. If an 
elective CA of AF is desired in patients with DT or 
TT the data supports a waiting strategy until the 
AAT can be discontinued to minimize the risk of 
peri-interventional bleedings. On the other hand, 
an earlier termination of AAT should be avoided 
due to the potential increased risk of mortality, 
for example, due to stent thrombosis. However, 
larger controlled studies are necessary for definite 
conclusions.
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